Cardiogenics Holding (CGNH) 0.0135 $CGNH
A.C. Simmonds And Sons Acquires Position In Cardiogenics Holdings Inc.
ACCESSWIRE - Tue Nov 17, 7:55AM CST
TORONTO, ON / ACCESSWIRE / November 17, 2015 / A.C. Simmonds and Sons Inc., (OTCPK:ACSX) announced today it has acquired, through a transfer of shares and assumption of debt, an equity position in CardioGenics Holdings Inc. A.C. Simmonds and Sons agreed to acquire a convertible debenture in the amount of $10,000,000 CDN (Ten Million Canadian Dollars) of CardioGenics Holdings Inc. (OTCQB:CGNH) and 15,000,000 common shares of CGNH and 10,000,000 cashless warrants at a strike price of $0.50 USD.
CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap
Marketwired - Wed Nov 04, 12:46PM CST
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 that it had entered into a binding letter of intent to acquire substantially all of Plasticap's assets.
CardioGenics Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap
Marketwired - Mon Oct 05, 8:01AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD" testing market, announced today that it has entered into a binding letter of intent to acquire substantially all of the assets of Plasticap ("LOI). CardioGenics previously announced on August 25, 2015 that it had entered into a manufacturing agreement with Plasticap, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care(TM) analyzer.
CardioGenics Enters Into Manufacturing Agreement With Ontario-Based Plasticap
Marketwired - Tue Aug 25, 8:02AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD" testing market, announced today that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care(TM) analyzer. The term of the agreement is 3 years and the purchase price for each cartridge shall be as specified in each purchase order issued pursuant to the agreement.
USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application
GlobeNewswire - Tue Feb 17, 8:50AM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD" testing market, announced today that the United States Patent & Trademark Office ("USPTO" has issued a Notice of Allowance with respect to certain patent claims contained in its patent application for the self-metering cartridge to be utilized in the Company's QL Care(TM) analyzer. The Notice of Allowance, which is the USPTO's notice to the Company that the allowed patent claims are entitled to patent protection, now clears the way for the issuance of the patent for the self-metering cartridge, upon payment of the applicable patent issuance fees.
CardioGenics Announces Appointment of New Director
GlobeNewswire - Mon Jan 12, 3:30PM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.
A.C. Simmonds And Sons Acquires Position In Cardiogenics Holdings Inc.
ACCESSWIRE - Tue Nov 17, 7:55AM CST
TORONTO, ON / ACCESSWIRE / November 17, 2015 / A.C. Simmonds and Sons Inc., (OTCPK:ACSX) announced today it has acquired, through a transfer of shares and assumption of debt, an equity position in CardioGenics Holdings Inc. A.C. Simmonds and Sons agreed to acquire a convertible debenture in the amount of $10,000,000 CDN (Ten Million Canadian Dollars) of CardioGenics Holdings Inc. (OTCQB:CGNH) and 15,000,000 common shares of CGNH and 10,000,000 cashless warrants at a strike price of $0.50 USD.
CardioGenics Enters Into Asset Purchase Agreement to Acquire All Assets of Ontario-Based Plasticap
Marketwired - Wed Nov 04, 12:46PM CST
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that it, and its newly created Canadian subsidiary, have entered into a definitive asset purchase agreement to acquire substantially all of the assets of Plasticap. CardioGenics previously announced on October 5, 2015 that it had entered into a binding letter of intent to acquire substantially all of Plasticap's assets. CardioGenics Enters Into Binding Letter of Intent to Acquire Assets of Ontario-Based Plasticap
Marketwired - Mon Oct 05, 8:01AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that it has entered into a binding letter of intent to acquire substantially all of the assets of Plasticap ("LOI). CardioGenics previously announced on August 25, 2015 that it had entered into a manufacturing agreement with Plasticap, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care(TM) analyzer. CardioGenics Enters Into Manufacturing Agreement With Ontario-Based Plasticap
Marketwired - Tue Aug 25, 8:02AM CDT
CardioGenics Holdings Inc. (OTCQB: CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics' proprietary self-metering cartridges for its QL Care(TM) analyzer. The term of the agreement is 3 years and the purchase price for each cartridge shall be as specified in each purchase order issued pursuant to the agreement. USPTO Issues Notice of Allowance in Connection With CardioGenics' Self-Metering Cartridge Patent Application
GlobeNewswire - Tue Feb 17, 8:50AM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics ("IVD"
testing market, announced today that the United States Patent & Trademark Office ("USPTO" has issued a Notice of Allowance with respect to certain patent claims contained in its patent application for the self-metering cartridge to be utilized in the Company's QL Care(TM) analyzer. The Notice of Allowance, which is the USPTO's notice to the Company that the allowed patent claims are entitled to patent protection, now clears the way for the issuance of the patent for the self-metering cartridge, upon payment of the applicable patent issuance fees. CardioGenics Announces Appointment of New Director
GlobeNewswire - Mon Jan 12, 3:30PM CST
CardioGenics Holdings Inc. (OTCQB:CGNH), developer of the ultra-sensitive QL Care(TM) analyzer, an immunoassay point-of-care analyzer, and other products for the In-Vitro-Diagnostics testing market, announced today that Karim Murabet has been appointed as a director of the Company, effective January 12, 2015. Mr. Murabet will serve as an independent director.
